Analgesics

In 2023, Australians suffered from an extended influenza season, with months where people were prone to sickness. Analgesics had already seen strong growth in the last few years due to widespread illness as a result of COVID-19.However, strong growth…

Analgesics has experienced a fluctuating performance in the last few years, as demand has been significantly impacted by the dramatic changes to consumer lifestyles resulting from the COVID-19 crisis. With the outbreak of COVID-19 in 2020, many…

Sales of analgesics return to their pre-pandemic performance in 2023. After the pandemic, seasonal colds and flus circulated more in the country as consumers socialised more without wearing masks, and sales of analgesics have returned to their usual…

Analgesics has not seen a positive performance in 2023 as the height of the pandemic has passed. During the pandemic’s peak, consumers were buying up analgesics at a rapid pace to treat fevers, aches and other symptoms associated with acute…

In 2023, acetaminophen continues to lead sales of analgesics in Chile, whilst also experiencing the highest growth rate in the category. This growth has remained steady since the onset of the pandemic, where acetaminophen became the preferred choice…

In the context of transforming the health system in Indonesia, one of the agendas currently being pursued by the Ministry of Health is to increase pharmaceutical resilience by increasing domestic production of the top 10 value medicines, which…

Demand for both adult and paediatric analgesics continued to grow in retail volume terms in 2023. Such products are widely used in Poland, particularly in the case of pain which is fleeting or immediate. With the rapid pace of modern life, consumers…

While analgesics performed well during the pandemic, they has returned to more moderate growth now that the threat has subsided. In 2023, analgesics is expected to register moderate current value growth, though constant value sales are expected to…

Sales of analgesics are seeing robust growth in current value terms in 2023, continuing on from the steady performance seen in 2022. During 2022, sales of analgesics benefited from a sudden peak in cases of flu in the middle of the winter. This was…

Analgesics is projected to continue to post fast retail volume growth over 2023. The potential for even higher growth is restricted by many households retaining stocks of analgesics purchased during the Coronavirus (COVID-19) pandemic. One clear…

In 2023, there have been stock shortages for some analgesics in key distribution channels in Saudi Arabia, resulting from producers, suppliers, and/or distributors. As a result, end consumers have been switching to alternative products containing the…

Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…

After the spike in demand for systemic analgesics in the period, 2020 to 2021, driven by COVID-19 and then by the need to relieve reactions to vaccination, in 2022 demand tended to stabilise. However, adult acetaminophen and combination analgesics…

Retail volume sales of analgesics rebounded in 2023, following a two-year period of decline. While the COVID-19 pandemic boosted demand for acetaminophen (paracetamol), which was the only analgesic recommended by the government to alleviate the…

Analgesics in Austria continued to see strong growth in retail current value sales terms in 2022, with positive, if more moderate, increments in retail volume terms. Growth was driven by sales of systemic and topical analgesics alike. Many consumers…

The pandemic boosted demand for analgesics in Vietnam, as consumers believed that it was necessary to store analgesics at home as a precautionary measure. Adult and paediatric acetaminophen performed particularly well in 2020 and 2021, as…

Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…

Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…

Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…

Following strong growth between 2020 and 2022, analgesics saw much more moderate current value growth in 2023 as the COVID-19 pandemic began to wane. Rising inflation as a result of the energy crisis stemming in part from the war in Ukraine is…